Cakmak Arzu, Posaci Cemal, Dogan Erbil, Caliskan Sezer, Guclu Serkan, Altunyurt Sabahattin
Department of Obstetrics and Gynecology, Dokuz Eylül University, Izmir, Turkey.
Am J Obstet Gynecol. 2005 Aug;193(2):347-51. doi: 10.1016/j.ajog.2005.01.023.
The purpose of this study was to investigate the effect of raloxifene on leptin and insulin-like growth factor-I levels and their relation with the biochemical markers of bone metabolism in postmenopausal women.
Sixty-four women were given 60 mg/d raloxifene for 6 months. Serum leptin, insulin-like growth factor-I, alkaline phosphatase, calcium, osteocalcin, and collagen type I cross-link C-telopeptide levels were measured before and after the treatment. The patients were grouped as obese (body mass index, > or =25 kg/m2) or non-obese (body mass index, <25 kg/m2).
The mean basal leptin level was significantly higher (P < .001), and the mean cross-link C-telopeptide level was significantly lower (P = .001) in obese patients. Raloxifene therapy increased leptin levels (P < .001) and decreased insulin-like growth factor-I, alkaline phosphatase, and cross-link C-telopeptide levels significantly (P < .001). There was a strong negative correlation between leptin and cross-link C-telopeptide (r = -0.703; P < .001). Insulin-like growth factor-I was not correlated with any parameter.
Raloxifene increases serum leptin levels while decreasing bone resorption in postmenopausal women.
本研究旨在探讨雷洛昔芬对绝经后女性瘦素和胰岛素样生长因子-I水平的影响及其与骨代谢生化标志物的关系。
64名女性接受60mg/d雷洛昔芬治疗6个月。在治疗前后测量血清瘦素、胰岛素样生长因子-I、碱性磷酸酶、钙、骨钙素和I型胶原交联C末端肽水平。患者被分为肥胖组（体重指数，≥25kg/m²）或非肥胖组（体重指数，<25kg/m²）。
肥胖患者的平均基础瘦素水平显著更高（P<.001），平均交联C末端肽水平显著更低（P=.001）。雷洛昔芬治疗可提高瘦素水平（P<.001），并显著降低胰岛素样生长因子-I、碱性磷酸酶和交联C末端肽水平（P<.001）。瘦素与交联C末端肽之间存在强负相关（r=-0.703；P<.001）。胰岛素样生长因子-I与任何参数均无相关性。
雷洛昔芬可提高绝经后女性的血清瘦素水平，同时减少骨吸收。
Zotero 插件